Furthermore, in breast cancer, both loss of E-cadherin and centrosome amplification have been independently associated with poor prognosis and more aggressive tumors (e.g., triple-negative breast cancer; D’Assoro et al., 2002; Kashiwagi et al., 2010; Denu et al., 2016). This evidence concerns the gene CDH1 and breast cancer.